Thermo Fisher Scientific has underperformed the broader market over the past year, but analysts are highly optimistic about ...

The stock's fall snapped a four-day winning streak.

Thermo Fisher Scientific has cleared a major regulatory hurdle in getting a new diagnostic tool for a type of blood cancer in ...

Thermo Fisher Scientific is breaking out the big bills to score a clinical research treat. With $8.875 billion in cash, the ...

Thermo Fisher Scientific received 510 (k) clearance from the Food and Drug Administration to market its EXENT system to aid in the diagnosis of multiple myeloma. The company's EXENT system detects and ...

NVIDIA, Micron Technology and Thermo Fisher lead today's top analyst picks, each showing strong growth trends and strategic advances.

Private equity-backed Clario brings to Thermo Fisher Scientific software that collects, manages, and analyzes clinical trial ...

Thermo Fisher’s Jennifer Cannon reviews the first year of the company’s Accelerator Drug Development suite of services and ...

Diamond Hill Capital, an investment management company, released its “Large Cap Fund” third-quarter 2025 investor letter. A ...

Thermo Fisher Scientific shares rise after announcing $8.875B acquisition of Clario, enhancing AI-powered clinical trials and digital drug development capabilities.

In addition to the initial cash purchase price at closing, Thermo Fisher has agreed to pay $125 million in January 2027.

The new system addresses challenges around food and water quality testing in the face of contaminants such as per- and ...